Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal

Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately $74 billion. This acquisition will merge two ... Read More